Wegovy, Saxenda, and Mounjaro are prescription-only medications with robust clinical evidence showing weight loss of 15-22% of body weight. In Singapore, access to these treatments is available through licensed medical clinics, including Noah's telehealth platform.
GLP-1 (glucagon-like peptide-1) receptor agonists were originally developed for type 2 diabetes management. GLP-1 is a hormone naturally released by the gut after eating. It stimulates insulin secretion, suppresses glucagon, slows gastric emptying, and acts on the hypothalamus to reduce appetite and food cravings.
Wegovy is administered as a once-weekly subcutaneous injection. The STEP 1 trial found semaglutide 2.4 mg produced mean weight loss of 14.9% of body weight over 68 weeks.
Saxenda is administered as a once-daily subcutaneous injection. The SCALE Obesity trial demonstrated mean weight loss of 8.0% of body weight over 56 weeks.
Mounjaro targets two gut hormone receptors - GLP-1 and GIP. The SURMOUNT-1 trial showed mean weight loss of up to 20.9% of body weight at the 15 mg dose over 72 weeks.
GLP-1 medications for weight management are indicated for:
A full medical assessment is essential before starting any GLP-1 medication.
The most common side effects are gastrointestinal and occur during dose escalation: nausea, vomiting, diarrhoea or constipation. These typically improve within a few weeks.
Noah is a licensed telehealth clinic in Singapore. All consultations are conducted by SMC-registered doctors.

